Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Providence, Rhode Island 02903


Purpose:

Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess the drug's ability to affect the evolution of malignant gliomas, when given as a capsule, rather than by intravenous injection.


Criteria:

Inclusion criteria: - Histologically confirmed diagnosis of a recurrent primary malignant glioma - Life expectancy of at least 3 months with normal hematological, liver and renal function Exclusion criteria: - Pregnant and lactating patients - Participation in any investigating drug study within 4 weeks preceding treatment start or concurrent treatment with any other anti-cancer therapy - Gastrointestinal dysfunction that could alter absorption or motility


NCT ID:

NCT00032903


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Providence, Rhode Island 02903
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 15, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.